OrbiMed’s Protagonist Therapeutics PTGX Stock Holding History

OrbiMed’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.4M	Buy	+150,000	New	+$15.7M	0.34%	67

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

OrbiMed's PTGX Position: Q2 2026 in Review

OrbiMed held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 42,100 shares worth $5.16M. The position accounts for 0.1% of the portfolio, ranked #102.

OrbiMed first reported a position in PTGX in Q4 2019 and has held it in 6 quarters since. The position peaked at $6.92M in Q1 2023. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

OrbiMed held 42,100 shares of Protagonist Therapeutics worth $5.16M as of Q2 2026.
OrbiMed left its Protagonist Therapeutics share count unchanged in Q2 2026.
Protagonist Therapeutics made up 0.1% of OrbiMed's portfolio in Q2 2026, its #102 holding.
OrbiMed first reported a position in Protagonist Therapeutics in Q4 2019 and has held it in 6 quarters since.
OrbiMed's Protagonist Therapeutics position peaked at $6.92M in Q1 2023.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.